Life Sciences

  • December 03, 2025

    Pharmacies Want Opioid Mistrial As Deliberations Stretch On

    The nation's three major pharmacy chains asked a Florida state judge Wednesday to declare a mistrial following 11 days of deliberations in a $1.5 billion case by hospitals over opioid dispensing, claiming jurors seem unaware that they are allowed to report a deadlock.

  • December 03, 2025

    Pharma Co. Exec Faces $125K SEC Judgment In Fraud Case

    A New York federal judge on Wednesday approved a $125,000 civil penalty against the former chief science officer of BioZone Pharmaceuticals Inc. for his alleged involvement in a purported pump-and-dump scheme involving the company's stock.

  • December 03, 2025

    NuVasive Urges Del. Justices To Revive Officer Conflict Suit

    A Delaware vice chancellor applied the wrong standards in tossing a suit alleging a former officer of spine surgery tech venture NuVasive Inc. ran an insider scheme to lure surgeons to a competitor while planning his own jump, an attorney for NuVasive told a Delaware Supreme Court panel on Wednesday.

  • December 03, 2025

    Kevin O'Leary, Company Execs Fight Patent Forgery Suit

    A livestock technology company and several of its executives and investors, including Kevin O'Leary of "Shark Tank," have asked a Colorado federal judge to throw out the lawsuit against them by the company's founder, who claims the defendants stole her company and intellectual property.

  • December 03, 2025

    'Dr. P.' Gets 2.5 Years For Selling Ketamine To Matthew Perry

    A California federal judge sentenced a former physician who supplied Matthew Perry with ketamine before the "Friends" actor's overdose death to 2 years and 6 months in prison Wednesday, following the doctor's July guilty plea to four counts of illegally distributing the drug.

  • December 03, 2025

    AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing

    AT&T has joined the bevy of litigants suing a swath of pharmaceutical companies over alleged generic drug price-fixing, claiming it shelled out billions of dollars for medication reimbursements to the drugmakers as part of its employee health plans when it could have spent far less if the drugs weren't subject to anticompetitive pricing.

  • December 03, 2025

    Novartis, Swiss Marketer Want Out Of Trade Secrets Suit

    A Swiss marketing company and its founder have joined pharmaceutical giant Novartis in asking a Manhattan federal judge to release them from a hedge fund's suit accusing the founder of brokering business meetings with Novartis in a scheme to steal its strategy, claiming the suit is merely an attempt to punish Novartis for placing money with a competitor.

  • December 03, 2025

    Fed. Circ. Backs Axed Claims In Heart Rate Monitor Patent

    The Federal Circuit on Wednesday upheld a Utah federal court's decision that claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy were invalid under the U.S. Supreme Court's Alice test.

  • December 03, 2025

    Judge To OK $16.5M 23andMe Insurer Buyback Deal In Ch. 11

    A Missouri bankruptcy judge Wednesday agreed to approve a $16.5 million settlement between genetic testing company 23andMe and its insurers, in which the carriers proposed to buy back the unused portion of their cyber coverage.

  • December 03, 2025

    AGs Say Sun, Taro Settlement Mustn't Touch State Claims

    State attorneys general have asked a Pennsylvania federal judge to again ensure their claims remain untouched by a settlement between private plaintiffs and generic-drug makers in sprawling price-fixing litigation, this time focusing on a $200 million deal between Sun Pharmaceutical, Taro Pharmaceuticals and employee benefit plans.

  • December 03, 2025

    7 Pension Funds Picked To Lead Neogen Investor Class

    A Michigan federal judge Wednesday selected a group of pension funds to serve as a lead plaintiff for Neogen investors alleging the company hid postmerger financial difficulties following a combination with a division of manufacturing giant 3M.

  • December 03, 2025

    WilmerHale Hires BNP Paribas Director In Boston

    An attorney with nearly 30 years of experience counseling clients on financial regulatory matters, including 10 years with the U.S. Department of the Treasury, has moved his practice to WilmerHale's Boston office.

  • December 02, 2025

    Squires Institutes First PTAB Challenges Since Taking Over

    U.S. Patent and Trademark Office Director John Squires has instituted four inter partes reviews and two post-grant reviews, the first Patent Trial and Appeal Board challenges to get his sign-off since he took over the institution review process.

  • December 02, 2025

    Judge Blocks Planned Parenthood Funding Cut In 22 States

    A Massachusetts federal judge Tuesday stopped the Trump administration from halting Medicaid reimbursements to Planned Parenthood clinics in 22 states, ruling the funding cutoff likely violated requirements to warn the states ahead of time about the change.

  • December 02, 2025

    9th Circ. Mulls Pharma Exec's Use Of Forced Arbitration Law

    A California biopharmaceutical company told the Ninth Circuit on Tuesday that a district court erred in letting its former chief financial officer move her discrimination claims out of arbitration and into federal court, saying she arbitrated too long before invoking the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act.

  • December 02, 2025

    U Of Colo. To Pay $10M In Religious Bias Suit Over Vax Policy

    The University of Colorado's medical school will pay $10.3 million to a group of employees and students who claimed in federal court that their religious exemption requests to the university's COVID-19 vaccine mandate were unlawfully denied, according to the group's attorneys.

  • December 02, 2025

    Monthly Merger Review Snapshot

    The FTC urged a D.C. court to block a deal involving a new heart valve treatment, and courts rejected the commission's monopolization case over Meta's past acquisitions and the agency's challenge of a medical device coatings deal. Here, Law360 looks at the major merger review developments from November.

  • December 02, 2025

    Defamation Litigation Roundup: FDA, Lively, Alexander Bros.

    In this month's review of defamation fights, Law360 highlights a pharmaceutical company's suit against a former U.S. Food and Drug Administration official, as well as the latest decision siding against President Donald Trump in his fights with media companies.

  • December 02, 2025

    UK Importer Must Pay Tax On PPE, Court Affirms

    A logistics company must pay £1.4 million ($1.8 million) in customs duties and value-added tax for personal protective equipment imported from China to the U.K. during the COVID-19 pandemic in 2020, a London court ruled, finding the business failed to comply with regulations to make those goods duty- and tax-free.

  • December 02, 2025

    Under New Chair, Fed. Vax Panel To Redo Hep B Vote

    The new chair of an influential federal vaccine advisory panel is set to lead a vote this week on whether to roll back federal recommendations that newborns get vaccinated against hepatitis B.

  • December 02, 2025

    Fed. Circ. Erases $41.8M Verdict Over Seagen Cancer Drug IP

    The Federal Circuit in a precedential opinion Tuesday reversed a $41.8 million verdict against Daiichi Sankyo for infringing a Seagen breast cancer treatment patent, saying a lower court should have found that the patent didn't adequately describe the claimed invention or enable a skilled person to use it.

  • December 02, 2025

    Hagens Berman Referred To DOJ For Alleged Misconduct

    A Pennsylvania federal judge on Tuesday recommended to the U.S. Department of Justice that it investigate powerhouse plaintiffs firm Hagens Berman Sobol Shapiro LLP's conduct in connection with several since-dropped product liability cases that a special master found to be filed in bad faith.

  • December 02, 2025

    MVP: Williams & Connolly's David M. Krinsky

    David M. Krinsky of Williams & Connolly LLP's life sciences practice represented Pfizer in patent infringement litigation filed by companies like Moderna and Enanta Pharmaceuticals Inc., and won a victory for Merck before the Federal Circuit, earning him a spot as one of the 2025 Law360 Life Sciences MVPs.

  • December 02, 2025

    CVS Will Pay $37.8M To Settle Insulin Pen Overbilling Claims

    CVS has agreed to pay $37.76 million to settle allegations that the major pharmacy retailer violated federal law by overdispensing and overbilling for insulin pens to government healthcare programs, federal prosecutors said Tuesday. 

  • December 01, 2025

    Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit

    A Manhattan federal judge Monday trimmed UMB Bank's lawsuit accusing Bristol-Myers Squibb of slow-walking the U.S. Food and Drug Administration approval process for three drugs to avoid paying shareholders $6.7 billion owed from its 2019 acquisition of Celgene Corp.

Expert Analysis

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.